Day: October 19, 2024

NYSE American to Commence Delisting Proceedings with Respect to the Warrants of Calidi Biotherapeutics, Inc. (CLDI WS)

Written by Customer Service on . Posted in Public Companies.

SAN DIEGO, Oct. 18, 2024 (GLOBE NEWSWIRE) — Calidi Biotherapeutics, Inc. (NYSE American: CLDI) (“Calidi”), a clinical-stage biotechnology company developing a new generation of targeted antitumor virotherapies, today announced that the staff of NYSE Regulation has determined to commence proceedings to delist the warrants — ticker symbol CLDI WS — of Calidi Biotherapeutics, Inc. (the “Company”), each whole warrant exercisable for 1/10th of a share of common stock at an exercise price of $115.00 per whole share of common stock, from the NYSE American. Trading in the Company’s warrants will be suspended immediately. Trading in the Company’s common stock — ticker symbol CLDI — will continue on the NYSE American. NYSE Regulation staff has determined that the Company’s warrants are no longer suitable for listing pursuant to Section 1001...

Continue reading

Tevogen CEO Expresses Gratitude for Unprecedented Public Support of Company’s Business Model of Commercial Success Through Patient Accessibility and Reaffirms His Commitment to Share Additional Details in the Coming Days

Written by Customer Service on . Posted in Public Companies.

WARREN, N.J., Oct. 18, 2024 (GLOBE NEWSWIRE) — Tevogen Bio (“Tevogen” or “Tevogen Bio Holdings Inc.”) (Nasdaq: TVGN) is a clinical-stage specialty immunotherapy biotech developing off-the-shelf, genetically unmodified T cell therapeutics to treat infectious disease and cancers. Since being founded in 2020, Tevogen Bio has taken a unique approach to both drug development and managing its business operations. The company launched is proprietary ExacTcell™ technology, designed to create accessible and disease-specific cellular immunotherapies. Tevogen Bio received 3 U.S. patents, with an additional 9 patents pending, including 2 for Artificial Intelligence, and has filed 12 international applications. Additionally, the company reported positive proof-of-concept clinical trial data for the first clinical product of its proprietary...

Continue reading

Apollo Silver Announces Further Upsizing of Private Placement

Written by Customer Service on . Posted in Public Companies.

VANCOUVER, British Columbia, Oct. 18, 2024 (GLOBE NEWSWIRE) — Apollo Silver Corp. (“Apollo Silver” or the “Company”) (TSX.V:APGO, OTCQB:APGOF, Frankfurt:6ZF0) is pleased to announce that due to significant interest, the Company has elected to further increase the size of its non-brokered private placement and will now offer up to 67,500,000 common shares of the Company (the “Shares”) at a price of $0.20 per Share, for aggregate gross proceeds of up to $13,500,000 (the “Offering”). All securities issued in connection with the Offering will be subject to a four-month hold period from the date of closing. Finder’s fees may be payable on a portion of the funds in accordance with the policies of the TSX Venture Exchange (the “TSX-V”). The Company intends on using the net proceeds from the Offering to continue advancing the Calico Silver...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Cookie Notice

We use cookies to improve your experience on our website

Information we collect about your use of Goldea Capital website

Goldea Capital website collects personal data about visitors to its website.

When someone visits our websites, we use a third party service, Google Analytics, to collect standard internet log information (such as IP address and type of browser they’re using) and details of visitor behavior patterns. We do this to allow us to keep track of the number of visitors to the various parts of the sites and understand how our website is used. We do not make any attempt to find out the identities or nature of those visiting our websites. We won’t share your information with any other organizations for marketing, market research or commercial purposes and we don’t pass on your details to other websites.

Use of cookies
Cookies are small text files that are placed on your computer or other device by websites that you visit. They are widely used to make websites work, or work more efficiently, as well as to provide information to the owners of the site.